Company Research Report: SmartCatch

Company Overview

• Name: SmartCatch

• Mission: Make the liquid biopsy of circulating tumor cells accessible to everyone.

• Foundation Year and Founders: Founded in September 2016 as a spin-off of the CNRS. Jointly founded by a team specializing in micro/nanotechnologies from the Laboratory of Architecture and Analysis of Systems (LAAS-CNRS) and urology surgeons from the University Institute of Cancer (IUCT) and Montauban Uropole in Toulouse.

• Key People:

• Aline Cerf, PhD - President & Co-Founder

• Bernard Malavaud, MD, PhD - Co-Founder

• Christophe Vieu, PhD - Head of Technology & Co-Founder

• Sylvain Sanson, MD, MSc - Co-Founder

• Mélanie Vernet - HR and Administrative Manager

• Yan Spenlinhauer - Industrial Manager

• Claire Labbe - Quality & Regulatory Affairs Manager

• Zacchari Ben Meriem, PhD - Innovation Manager

• Emilie Nicole - Chief Financial Officer

• Headquarters: 1 Place Pierre Potier, 31100 Toulouse, France

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Developing innovative microfiltration devices for liquid biopsy, focusing on the diagnosis, follow-up, and personalization of cancer care through the isolation of Circulating Tumor Cells (CTC).

Products

• X-Tracker

• Description: A fully-automatized benchtop system designed for the efficient capture and isolation of circulating tumor cells (CTCs) from blood samples in vivo conditions.

• Key Features:

• Single-step enrichment for untreated biofluid with viable, unaltered cells.

• Compatible with multiple biofluids (6–45 ml).

• User-friendly, automatized, fast, with minimal training required and compact design.

• Suitable for applications in oncology, drug discovery, proteomics, transcriptomics, and functional studies.

• Compatible with analytical techniques like enumeration, morphology, molecular analysis, and proteomics.

Recent Developments

• Recent Achievements:

• SmartCatch has been named as Hello Tomorrow Deep Tech Pioneer in December 2022.

• In a 2023 article in La Vie Economique, CEO Aline Cerf shared insights on the future of revolutionary cancer care technology.

• Featured in the 2023 issue of LES ECHOS, highlighting their €3.2 million investment to develop a medical device for hospitals.

• Nominated for the 2024 Prix Galien USA Awards for Best Startups.

• Featured in ToulEco magazine for CEO Aline Cerf's innovative approaches in cancer care.

• New Partnerships: No information is available.

The above report synthesizes available data on SmartCatch, focusing on its foundation, mission, products, and recent notable developments to provide a comprehensive overview without speculation or extrapolation beyond the data provided.